Skip to main content
. Author manuscript; available in PMC: 2024 Dec 11.
Published in final edited form as: Drug Discov Today. 2018 May 7;23(6):1293–1304. doi: 10.1016/j.drudis.2018.05.012

Figure 3.

Figure 3

Naringin effectively inhibits bone resorption in vitro. (A) Representative scanning electron microscopy (SEM) micrographs of bone resorption pits induced by osteoclast-like cells in bovine bone slices after incubation with different naringin doses (0, 0.5 and 1 mM) for 24 h. (B) Total resorption pit areas of each treatment group as measured under SEM. (C) Microscopic view of TRAP-stained osteoclasts in calvarial bone cultures treated with different doses of naringin for 10 days. (D) Number of TRAP-stained osteoclast cells treated with different doses of naringin for 1, 3,7 and 10 days. *p < 0.05, **p < 0.01, ***p < 0.001. All data above is represented in mean ± s.d. (n=3). Adapted from reference [30] with permission Wiley. Adapted from reference [34] under a Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/).